Radioactively labeled nucleoside triphosphates ntps

Remdesivir (RDV, GS-5734), its parent nucleoside GS-441524, metabolite intermediate GS-704277 (Met X), and 5′-triphosphorylated metabolite GS-443902 were synthesized by Gilead Sciences, Inc. (Foster City, CA). Nucleotide triphosphates (TP) used as positive controls, including decitabine-TP (5-aza-2′-deoxyCTP), 2′CMe-GTP (active metabolite of BMS-986094), 4′-CN-CTP (active metabolite of Balapiravir/RG1626) were synthesized by Gilead Sciences, Inc. 3′-Deoxy ATP, 3′-deoxy GTP, 3′-deoxy CTP, and 3′-deoxy UTP were purchased from TriLink BioTechnologies (San Diego, CA). Control compounds for CC₅₀ assays, such as dideoxycytidine (ddC), puromycin, chloramphenicol, menadione, aphidicolin, and α-amanitin, were purchased from Sigma-Aldrich (St. Louis, MO). All radioactively labeled nucleoside triphosphates (NTPs) were purchased from PerkinElmer (Shelton, CT).